More than 30 new TB vaccines have entered development over the past twenty years.

Several have failed; others are have not reached the clinic; a few are in early stages of development.

The only new TB vaccine to have shown efficacy in humans in a fully-powered Phase 3 trial (NTC00052195) is the booster vaccine being developed by investigators at Dartmouth College.

The DarDar Trial, a 7-year, 2,000-subject rigorously designed trial conducted in Tanzania and sponsored by the National Institutes of Health showed that SRL172, a inactivated, whole cell vaccine prepared from an environmental mycobacteria, was safe and effective in persons with HIV infection (von Reyn et al AIDS 2010; 24: 675-685).